Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04087629 · ClinicalTrials.gov registry record · NA
StrataCTX® as a Steroid Sparing Device
A NA study of CTCL, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT04087629: Recruiting NA study of CTCL, sponsored by Columbia University.
NCT04087629 is a NA study of CTCL that is actively recruiting participants, run by Columbia University. The registered enrollment target is 70 participants, above the 59-participant average among 4 other CTCL trials with a reported enrollment target (19% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04087629, a NA study of CTCL, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Primary Outcome
The primary objective of this study is to determine whether StrataCTX® gel is effective as a supportive therapy for cutaneous reactions treated with topical steroids as the standard of care. This objective will be measured by the Pruritus Visual Analogue Scale, which measures self-reported itching on a scale of 0 (no itching) (better outcome) to 10 (worst imaginable itch).
Conditions Studied
Interventions
- DEVICE StrataCTX® gel
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT04087629 shows while recruiting
NCT04087629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 59-participant average among 4 other CTCL trials with a reported enrollment target (19% higher).
The record links to 1 condition, with CTCL appearing as the primary indexed condition, and to 1 intervention - of which StrataCTX® gel is the first listed.
NCT04087629 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04087629 about?
NCT04087629 is a clinical study titled "StrataCTX® as a Steroid Sparing Device". The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatm...
What is the current status of trial NCT04087629?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2021-07-07. Estimated completion is 2026-08.
What conditions does trial NCT04087629 study?
This clinical trial studies the following conditions: CTCL.
What interventions are being tested in trial NCT04087629?
The interventions under investigation include: StrataCTX® gel (DEVICE).
Who is sponsoring clinical trial NCT04087629?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04087629 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTCL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
-
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RECRUITING · Phase 2
-
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI